Literature DB >> 6155772

Oxatomide: inhibition and stimulation of histamine release from human lung and leucocytes in vitro.

M K Church, C F Gradidge.   

Abstract

Oxatomide is a very potent inhibitor of histamine release induced by anti-1gE and Timothy pollen extract in passively sensitized human lung fragments and that induced by anti-1gE from human leucocytes. Its spectrum of activity is different from sodium cromoglycate-like drugs. In high concentrations oxatomide, like other antihistamines and related structures, induced histamine release from both lung and leucocytes. However, oxatomide induced histamine release far more effectively from sensitized lung than non-sensitized lung. Inhibition of immunologically induced histamine releast by oxatomide may play a part in its action as an anti-hay fever and, possibly, an anti-asthmatic drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155772     DOI: 10.1007/BF02024171

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  9 in total

1.  Morphological evaluation of oxatomide--a new anti-allergic drug in guinea pig anaphylaxis.

Authors:  M Borgers; M De Brabander; J Van Reempts; F Awouters; P A Janssen
Journal:  Int Arch Allergy Appl Immunol       Date:  1978

2.  Oxatomide, a new orally active drug which inhibits both the release and the effects of allergic mediators.

Authors:  F Awouters; C J Niemegeers; J Van den Berk; J M Van Neuten; F M Lenaerts; M Borgers; K H Schellekens; A Broeckaert; J De Cree; P A Janssen
Journal:  Experientia       Date:  1977-12-15

3.  An automated fluorimetric assay for the rapid determination of histamine in biological fluids.

Authors:  D P Evans; J A Lewis; D S Thomson
Journal:  Life Sci II       Date:  1973-04-08

4.  Inhibition of histamine release from human lung in vitro by antihistamines and related drugs.

Authors:  M K Church; C F Gradidge
Journal:  Br J Pharmacol       Date:  1980-08       Impact factor: 8.739

5.  Oxatomide protects Trichinella spiralis infected mice from lethal anaphylaxis.

Authors:  F De Clerck; L Van Gorp; O Vanparijs; M Borgers; F Awouters
Journal:  Agents Actions       Date:  1978-12

6.  The activity of sodium cromoglycate analogues in human lung in vitro: a comparison with rat passive cutaneous anaphylaxis and clinical efficacy.

Authors:  M K Church; C F Gradidge
Journal:  Br J Pharmacol       Date:  1980-10       Impact factor: 8.739

7.  Double-blind placebo-controlled clinical evaluation of oxatimide (R 35443). A novel potent anti-allergic drug in the treatment of hay fever.

Authors:  R de Beule; E Vannieuwenhuyse; J Callier; W Verstraete; F Degreef; M Gregoire; Y Robience; W Stevens; P Libert
Journal:  Acta Allergol       Date:  1977-08

8.  The effect of sodium 5,6-dimethyl-2-nitroindanedione on anaphylactic reactions in vitro.

Authors:  T J Sharpe; J W Ross; B A Spicer
Journal:  Agents Actions       Date:  1978-04

9.  STUDIES ON THE MECHANISMS OF HYPERSENSITIVITY PHENOMENA. IX. HISTAMINE RELEASE FROM HUMAN LEUKOCYTES BY RAGWEED POLLEN ANTIGEN.

Authors:  L M LICHTENSTEIN; A G OSLER
Journal:  J Exp Med       Date:  1964-10-01       Impact factor: 14.307

  9 in total
  5 in total

1.  Effect of ketotifen and oxatomide on histamine secretion from mast cells.

Authors:  A Truneh; J R White; F L Pearce
Journal:  Agents Actions       Date:  1982-04

2.  H1-antihistamines and calmodulin antagonists inhibit the ionophore A23187-induced eicosanoid formation by human leukocytes.

Authors:  T Simmet; W Luck
Journal:  Agents Actions       Date:  1989-03

3.  Comparative effects of oxatomide on the release of histamine from rat peritoneal mast cells.

Authors:  F De Clerck; J Van Reempts; M Borgers
Journal:  Agents Actions       Date:  1981-05

Review 4.  Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-07       Impact factor: 9.546

Review 5.  Oxatomide. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.